Organon & Co.
OGN · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.27 | 0.32 | -0.24 | -0.15 |
| FCF Yield | 15.33% | 14.62% | 6.07% | 25.52% |
| EV / EBITDA | 7.51 | 8.30 | 8.83 | 8.25 |
| Quality | ||||
| ROIC | 15.29% | 21.94% | 16.39% | 20.79% |
| Gross Margin | 58.02% | 59.84% | 62.84% | 62.21% |
| Cash Conversion Ratio | 1.09 | 0.78 | 0.94 | 1.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.22% | -0.22% | -1.86% | -6.76% |
| Free Cash Flow Growth | 9.29% | 24.83% | -78.12% | 3.20% |
| Safety | ||||
| Net Debt / EBITDA | 5.12 | 5.74 | 4.79 | 4.35 |
| Interest Coverage | 2.86 | 2.52 | 4.04 | 7.42 |
| Efficiency | ||||
| Inventory Turnover | 2.03 | 1.91 | 2.29 | 2.60 |
| Cash Conversion Cycle | 100.22 | 101.78 | 66.68 | 8.46 |